Related Experiment Video
Updated: Aug 21, 2026
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes
Olaf J C Hellwinkel1, Jürgen Müller, Annika Pollmann
1Department of Pediatric Hematology and Oncology, Clinic of Children's Health, University-Hospital Eppendorf, Hamburg, Germany. hellwinkel@uke.uni-hamburg.de
Background:
One of the most widely studied gene therapeutic strategies for cancer is the introduction of tumour-suppressor genes-generally p53-into the target cells. As the genes of p53 and/or retinoblastoma (Rb) are mutated in the major part of osteosarcomas (OS), we aimed to study the effect of p53 and Rb transgenes on a panel of five different osteosarcoma cell lines.
Methods:
OS cell lines were transduced by adenoviral vectors delivering the transcription units of the wildtype p53 and the Rb gene. Effects of the transgenes alone and at additional cytostatic stress were studied by proliferation, alive/dead and cell cycle assays.
Results:
The individual cells lines displayed divergent reactions to p53- or Rb-transgene delivery reaching from cell death (SaOs-2, U2OS at p53 transduction) over stopped or lowered cell division (MG-63, K-HOS, SJSA-1 at p53 and Rb transduction) to nearly unhindered cell growth (U2OS at Rb transduction). In those OS cell lines reacting with lowered cell division to p53 or Rb delivery, cytostatics only moderately intensified the transgene effects. Surprisingly, these reactions were apparently not dependent on the functional status of the cellular p53 and/or Rb genes or on differences in the infectability of the cell lines by the adenoviral vectors. Most interestingly, the respective effects of the p53 or Rb transgenes were not multiplied by simultaneous transduction of both tumour-suppressor genes.
Conclusions:
The application of wildtype tumour-suppressor gene therapy on genetically variable osteosarcomas may be efficient only in yet not identified genetic subgroups of this tumour entity. Hyperactive tumour-suppressor transgenes could be an alternative.
Insights
Gene therapy using p53 and retinoblastoma (Rb) transgenes showed varied effects on osteosarcoma cell lines. Simultaneous delivery of both tumor-suppressor genes did not enhance outcomes, suggesting tailored approaches for specific genetic subgroups.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Osteosarcoma (OS) is a common bone cancer with frequent mutations in tumor suppressor genes like p53 and retinoblastoma (Rb).
- Gene therapy, particularly introducing tumor suppressor genes, is a studied approach for cancer treatment.
Purpose of the Study:
- To investigate the effects of wildtype p53 and Rb transgenes on five different osteosarcoma cell lines.
- To assess the impact of these transgenes alone and under cytostatic stress.
Main Methods:
- Adenoviral vectors were used to deliver p53 and Rb genes into OS cell lines.
- Proliferation, viability (alive/dead), and cell cycle assays were performed to evaluate transgene effects.
Main Results:
- Osteosarcoma cell lines exhibited diverse responses to p53 and Rb transgene delivery, including cell death, growth inhibition, or minimal impact.
- The effects of transgenes were not consistently enhanced by cytostatic drugs or dependent on endogenous gene status or vector infectability.
- Simultaneous delivery of both p53 and Rb transgenes did not yield synergistic effects.
Conclusions:
- Wildtype tumor-suppressor gene therapy efficacy in osteosarcoma may be limited to specific genetic subgroups.
- Exploring hyperactive tumor-suppressor transgenes could be a potential alternative therapeutic strategy.
Related Concept Videos
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:23Negative Regulator Molecules